Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 91 to 105 of 556 results for compare

  1. Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

    Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA395

  2. For people with active, drug susceptible TB who experience treatment interruptions because of adverse events, particularly hepatotoxicity, what approach to re-establishing treatment is mosteffective in reducing mortality and morbidity?

    adverse events is also important. Randomised controlled trials are needed to compare approaches to re-establishing treatment for active,...

    Research recommendation
    Published
    8 November 2019

  3. Science policy and methods projects

    Science policy projects with NICE.

  4. Long‑term consequences of planning birth in different settings: What are the long‑term consequences for women and babies of planning birth in different settings?

    relation to place of birth. A large population‑based observational study would compare women's experiences and outcomes in different...

    Research recommendation
    Published
    6 January 2023

  5. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

    Technology appraisal guidance
    Published
    11 October 2017
    View recommendations

    Sections for TA482

  6. Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.

    Technology appraisal guidance
    Published
    24 July 2019
    View recommendations

    Sections for TA589

  7. Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)

    Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

    Technology appraisal guidance
    Published
    28 July 2021
    View recommendations

    Sections for TA716

  8. Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)

    Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.

    Technology appraisal guidance
    Published
    26 April 2017
    View recommendations

    Sections for TA440

  9. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    17 October 2023
    View recommendations

    Sections for TA927

  10. Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

    HealthTech guidance
    Published
    3 September 2020
    View recommendations

    Sections for HTG554

  11. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

    HealthTech guidance
    Published
    24 June 2020
    View recommendations

    Sections for HTG545

  12. HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)

    NICE has developed a medtech innovation briefing (MIB) on HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer .

    Medtech innovation briefing
    Published
    7 November 2017

  13. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)

    Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

    Technology appraisal guidance
    Published
    11 December 2024
    View recommendations

    Sections for TA1023

  14. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 October 2020

    Sections for TA654

  15. What is the clinical and cost effectiveness of humeral hemiarthroplasty compared with conventional total shoulder replacement for adults aged under 60 having primary elective shoulder replacement for osteoarthritis with no rotator cuff tear?

    this age group, so the committee made a recommendation for research to compare conventional total shoulder replacement with humeral...

    Research recommendation
    Published
    10 August 2020